Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Genomic profiling has transformed cancer treatment, particularly for oncogene-driven cancers like epidermal growth factor receptor (EGFR) mutant carcinoma.
• Rearranged during transfection (RET) rearrangements are key oncogenes implicated in carcinogenesis, leading to resistance against EGFR tyrosine kinase inhibitors and immunotherapy.
• Targeted therapies, including multi-kinase and selective RET inhibitors, are being investigated for RET rearrangement-driven cancers.

Purpose of the Study:

• To review the current challenges and dilemmas associated with targeted therapies for RET rearrangement cancers.
• To analyze preclinical and clinical studies on RET-targeted treatments.
• To propose clinical considerations for the future management of RET rearrangement-driven cancers.

Main Methods:

• Literature review of preclinical and clinical studies on targeted therapies for RET rearrangement cancers.
• Analysis of efficacy, toxicity, and limitations of existing and novel therapeutic strategies.
• Synthesis of findings to inform clinical practice.

Main Results:

• Multi-kinase inhibitors show limitations including modest efficacy, significant toxicity, and poor outcomes in brain metastasis.
• Selective RET inhibitors demonstrate promising results in ongoing clinical trials.
• RET rearrangements confer resistance to established therapies like EGFR inhibitors and immunotherapy.

Conclusions:

• Despite challenges with current targeted therapies for RET rearrangement cancers, selective RET inhibitors represent a promising therapeutic avenue.
• Addressing limitations such as efficacy and toxicity is crucial for improving patient outcomes.
• Further clinical considerations are needed to optimize the use of targeted therapies in RET-driven malignancies.